Journals / Çocuk Dergisi / 2004 / Cilt: 4 - Sayı: 4

A neuroblastoma case who presented with myoclonus-opsoclonus-ataxia

Miyoklonus-opsoklonus-ataksi ile başvuran nöroblastom vakası

Pages
254–256
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

MOA in a 22-month old girl with neuroblastoma is presented and discussed in the highlights of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myoclonus-opsoclonus-ataxia (MOA) is a paraneoplastic syndrome that is seen in about 2-3 % of children with neu-roblastoma.
📊
Key Findings & Data:In association with the good prognostic factors like early stage illness and favourable histological findings, it usually shows a higher survival rate, but the patients are under the risk of developing late neurological complications that may be immunologically mediated.
💡
Conclusion & Impact:MOA in a 22-month old girl with neuroblastoma is presented and discussed in the highlights of the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Oküler hareket bozuklukları · Paraneoplastik sendromlar · sinir sistemi

Abstract

Myoclonus-opsoclonus-ataxia (MOA) is a paraneoplastic syndrome that is seen in about 2-3 % of children with neu-roblastoma. Because of its good response to steroid therapy and presence of neurological signs without central nervous system involvement, it is thought to be immune mediated. In association with the good prognostic factors like early stage illness and favourable histological findings, it usually shows a higher survival rate, but the patients are under the risk of developing late neurological complications that may be immunologically mediated. MOA in a 22-month old girl with neuroblastoma is presented and discussed in the highlights of the literature.

Özet

Myoklonus-opsoklonus-ataksi (MOA), nöroblastomlu çocukların % 2-3'ünde görülen bir paraneoplastik sendromdur. Merkezi sinir sistemi tutulumu olmaksızın nörolojik bulguların olması ve steroid tedavisine iyi yanıt vermesi nedeniyle immun kaynaklı olduğu düşünülmektedir. Genellikle iyi histoloji ve erken evre hastalık gibi iyi prognostik kriterlerle birliktelik göstermesi nedeniyle sağkalım beklentisi yüksektir. Ancak, hastalar immun kaynaklı olduğu düşünülen geç nörolojik komplikasyonlar açısından risk altındadır. MOA sendromu ile başvuran ve nöroblastom tanısı konulan 22 aylık kız hasta sunuldu ve literatür eşliğinde tartışıldı.

🔖

Cite This Article

AKÇAY, A., AYDOĞAN, G., AKICI, F., SALCIOĞLU, Z. (2004). A neuroblastoma case who presented with myoclonus-opsoclonus-ataxia. Çocuk Dergisi, Cilt: 4 - Sayı: 4, 254–256. https://ajindex.com/articles/348633

References (15)

  1. Vukelic D, Bozinovic D, Norovic C, et al. Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect 2000
  2. Plantaz D, Michon J, Valteau-Couanet D, et al. Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists. Arch Pediatr 2000
  3. Rodriguez-Barrionuevo AC, Caballero-Morales MA, Delgado-Marques MP, et al. Kinsboume syndrome: review of our cases. Rev Neurol 1998
  4. Parisi MT, Hattner RS, Matthay KK, et al. Optomized diagnostic strategy for neuroblastoma in opsoclonus-myoclonus. J Nucl Med 1993
  5. Talon P, Stoll C. Opsomyoclonus syndrome in children. A new case. Review of the literature (110 cases). Pediatrie 1985
  6. Corrias A, Nurch AM, Rossi G, et al. Opsoclonic encephalopaty in childhood (Kinsboume syndrome). Pediatr Med Chir 1985
  7. Cooper R, Khakoo Y, Matthay KK, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 2001
  8. Hay ward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavi-oral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001
  9. Rudnick E, Khakoo Y, Altunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001
  10. Noetzel MJ, Cawley LP, James VL, et al. Anti-neurofilament protein antibodies in opsoclonus-myoclonus. J Neuroimmunol 1987
  11. Connolly AM, Pestronk A, Mehta S, et al. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997
  12. Boltshauser E, Deonna T, Hirt HR. Myoclonic encephalopaty of infants or 'dancing eyes syndrome'. Report of 7 cases with long-term follow-up and. review of the literature (cases with and without neuroblastoma). Helv Paediatr Acta 1979
  13. Hiyama E, Yokoyama T, Ichikawa T, et al. Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome. Cancer 1994
  14. Heyer R, Hamann J, Offner G, et al. Myoclonic encephalopathy in childhood. Monatsschr Kinderheilkd 1977
  15. Altunes NL, Khakoo Y, Matthay KK, et al. Antin